158 related articles for article (PubMed ID: 29337597)
21. Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy Pattern.
Iqbal A; Ansari SH; Parveen S; Khan IA; Siddiqui AJ; Musharraf SG
Sci Rep; 2018 Oct; 8(1):15152. PubMed ID: 30310134
[TBL] [Abstract][Full Text] [Related]
22. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia.
Hoppe C; Vichinsky E; Lewis B; Foote D; Styles L
Am J Hematol; 1999 Dec; 62(4):221-7. PubMed ID: 10589077
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India.
Bohara VV; Ray S; Chakrabarti P; Ray SS; Nath UK; Chaudhuri U
Hemoglobin; 2014; 38(1):44-8. PubMed ID: 24144212
[TBL] [Abstract][Full Text] [Related]
24. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.
Karimi M; Darzi H; Yavarian M
J Pediatr Hematol Oncol; 2005 Jul; 27(7):380-5. PubMed ID: 16012328
[TBL] [Abstract][Full Text] [Related]
25. The use of hydroxyurea in the real life of MIOT network: an observational study.
Ricchi P; Meloni A; Rigano P; Pistoia L; Spasiano A; Allò M; Messina G; Quarta A; Rosso R; Quota A; Filosa A; Maggio A; Pepe A
Expert Opin Drug Saf; 2022 Nov; 21(11):1433-1440. PubMed ID: 35435090
[TBL] [Abstract][Full Text] [Related]
26. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
[TBL] [Abstract][Full Text] [Related]
28. Effect of the Hydoxyurea in Yemeni Transfusion-Dependent β-Thalassemia Patients.
Al-Nood HA; Al-Nood RM; Ghanem NS; Al-Hadi AM
Hemoglobin; 2020 Mar; 44(2):104-108. PubMed ID: 32308066
[TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports.
Karimi M; Cohan N; Pishdad P
Hematology; 2015 Jan; 20(1):53-7. PubMed ID: 24717020
[TBL] [Abstract][Full Text] [Related]
30. Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy in β-Thalassemia Patients.
Zohaib M; Ansari SH; Hashim Z; Shamsi TS; Zarina S
J Clin Pharmacol; 2016 Jul; 56(7):869-74. PubMed ID: 26608512
[TBL] [Abstract][Full Text] [Related]
31. Use of hydroxyurea and recombinant erythropoietin in management of homozygous beta0 thalassemia.
Kohli-Kumar M; Marandi H; Keller MA; Guertin K; Hvizdala E
J Pediatr Hematol Oncol; 2002 Dec; 24(9):777-8. PubMed ID: 12468925
[TBL] [Abstract][Full Text] [Related]
32. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Banan M; Bayat H; Azarkeivan A; Mohammadparast S; Kamali K; Farashi S; Bayat N; Khani MH; Neishabury M; Najmabadi H
Hemoglobin; 2012; 36(4):371-80. PubMed ID: 22686296
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis.
Hatamleh MI; Chenna VSH; Contractor H; Krishna Mohan GV; Tirumandyam G; Dammas N; Khan MW; Hirani S
Cureus; 2023 Apr; 15(4):e38135. PubMed ID: 37252463
[TBL] [Abstract][Full Text] [Related]
34. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
Bradai M; Pissard S; Abad MT; Dechartres A; Ribeil JA; Landais P; de Montalembert M
Transfusion; 2007 Oct; 47(10):1830-6. PubMed ID: 17880608
[TBL] [Abstract][Full Text] [Related]
35. Hydroxyurea in thalassemia intermedia--a promising therapy.
Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
[TBL] [Abstract][Full Text] [Related]
36. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
Karimi M; Mohammadi F; Behmanesh F; Samani SM; Borzouee M; Amoozgar H; Haghpanah S
Eur J Haematol; 2010 Jan; 84(1):52-8. PubMed ID: 19799627
[TBL] [Abstract][Full Text] [Related]
37. Impact of hydroxyurea therapy on serum fatty acids of β-thalassemia patients.
Iqbal A; Siddiqui AJ; Huang JH; Ansari SH; Musharraf SG
Metabolomics; 2018 Jan; 14(3):27. PubMed ID: 30830370
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia.
Haghpanah S; Zarei T; Eshghi P; Zekavat O; Bordbar M; Hoormand M; Karimi M
Ann Hematol; 2018 Oct; 97(10):1919-1924. PubMed ID: 29926158
[TBL] [Abstract][Full Text] [Related]
39. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
[TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea therapy in 49 patients with major beta-thalassemia.
Zamani F; Shakeri R; Eslami SM; Razavi SM; Basi A
Arch Iran Med; 2009 May; 12(3):295-7. PubMed ID: 19400608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
